Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK government recognises perils of reference pricing in light of new value based pricing system

This article was originally published in Scrip

Executive Summary

The UK government says it recognises that it needs to "be careful" with regard to reference pricing as it prepares to move forward with plans for a new value based pricing system. Earl Howe, under secretary for England's department of health, has hinted that the government was considering mechanisms that would shield industry from reference pricing by allowing companies to offer discounts on the agreed value or list price.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC012966

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel